Abstract
Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) studies were carried out for a series of thienopyrimidines, novel Histamine H1 receptor antagonists. Various models were generated. The best predictive CoMFA model gave significant correlation coefficients (cross-validated r2 (q2) = 0.514, non-cross-validated r2 = 0.925), showing the influence of steric and electrostatic fields. Likewise, the best predictive CoMSIA model gave cross-validated r2 (q2) = 0.541, non-cross-validated r2 = 0.862, eliciting the influence of steric, electrostatic, hydrophobic and hydrogen bond acceptor fields. The generated models were externally validated and well correlated with calculated (predicted) and experimental inhibitory concentration (IC50) values, using test sets. The analysis of the contour maps of both CoMFA and CoMSIA models offer important structural insight for designing novel and more active Histamine H1 receptor antagonists prior to their synthesis.
Keywords: CoMFA, CoMSIA, Thienopyrimidine derivatives, 3D QSAR, Histamine, gastric acid, rhinitis, urticaria, fever, asthma
Medicinal Chemistry
Title:CoMFA and CoMSIA 3D QSAR Models for a Series of Some Condensed Thieno[2,3-d]pyrimidin-4(3H)-ones with Antihistaminic (H1) Activity
Volume: 9 Issue: 3
Author(s): Meenakshi Singh, Sushil K. Singh, Mahesh T. Chhabria, Kamala Vasu and Dhaivat Pandya
Affiliation:
Keywords: CoMFA, CoMSIA, Thienopyrimidine derivatives, 3D QSAR, Histamine, gastric acid, rhinitis, urticaria, fever, asthma
Abstract: Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) studies were carried out for a series of thienopyrimidines, novel Histamine H1 receptor antagonists. Various models were generated. The best predictive CoMFA model gave significant correlation coefficients (cross-validated r2 (q2) = 0.514, non-cross-validated r2 = 0.925), showing the influence of steric and electrostatic fields. Likewise, the best predictive CoMSIA model gave cross-validated r2 (q2) = 0.541, non-cross-validated r2 = 0.862, eliciting the influence of steric, electrostatic, hydrophobic and hydrogen bond acceptor fields. The generated models were externally validated and well correlated with calculated (predicted) and experimental inhibitory concentration (IC50) values, using test sets. The analysis of the contour maps of both CoMFA and CoMSIA models offer important structural insight for designing novel and more active Histamine H1 receptor antagonists prior to their synthesis.
Export Options
About this article
Cite this article as:
Singh Meenakshi, K. Singh Sushil, T. Chhabria Mahesh, Vasu Kamala and Pandya Dhaivat, CoMFA and CoMSIA 3D QSAR Models for a Series of Some Condensed Thieno[2,3-d]pyrimidin-4(3H)-ones with Antihistaminic (H1) Activity, Medicinal Chemistry 2013; 9 (3) . https://dx.doi.org/10.2174/1573406411309030010
DOI https://dx.doi.org/10.2174/1573406411309030010 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Concise Update on the Relevance of Secretory Phospholipase A2 Group IIA and its Inhibitors with Cancer
Medicinal Chemistry Bangladeshi Medicinal Plant Extracts Inhibiting Molecular Interactions between Nuclear Factors and Target DNA Sequences Mimicking NF-kB Binding Sites
Medicinal Chemistry Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets Children with Medical Complexity: Forwarding a Policy Agenda
Current Pediatric Reviews Pain Perception and Management: Where do We Stand?
Current Molecular Pharmacology Antioxidant Phytochemicals in Pulses and their Relation to Human Health: A Review
Current Pharmaceutical Design Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Chemokines in Allergic Aspergillosis - From Animal Models to Human Lung Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Kolaviron, A Biflavonoid Compound: Its Pharmacological Activity and Therapeutic Efficacy
Current Bioactive Compounds Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies Pathway-Specific, Species, and Sub-Type Counterscreening for Better GPCR Hits in High Throughput Screening
Current Pharmaceutical Biotechnology The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications
Current Medicinal Chemistry Progress in Research of K<sub>V</sub>1.1 and K<sub>V</sub>1.3 Channels as Therapeutic Targets
Current Topics in Medicinal Chemistry Self-Assembled Peptide Nanoarchitectures: Applications and Future Aspects
Current Topics in Medicinal Chemistry Structure and Function of Poly(ADP-ribose) Polymerase-1: Role in Oxidative Stress-Related Pathologies
Current Vascular Pharmacology Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Th17 Cells: The Role in Immunity
Current Immunology Reviews (Discontinued) Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Chronopharmaceutical Delivery of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry